WallStreetZenWallStreetZen

NASDAQ: GENB
Generate Biomedicines Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for GENB

Based on 5 analysts offering 12 month price targets for Generate Biomedicines Inc

Min Forecast
$22.00+34.23%
Avg Forecast
$26.40+61.07%
Max Forecast
$30.00+83.04%

Should I buy or sell GENB stock?

Based on 6 analysts offering ratings for Generate Biomedicines Inc.

Strong Buy
Strong Buy
5 analysts 83.33%
Buy
1 analysts 16.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although GENB's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates GENB as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their GENB stock forecasts and price targets.

GENB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-08
lockedlocked$00.00+00.00%2026-05-14
lockedlocked$00.00+00.00%2026-03-24
lockedlocked$00.00+00.00%2026-03-24
lockedlocked$00.00+00.00%2026-03-24
Guggenheim
Top 2%
99
Strong BuyInitiates Coverage On$30.00+83.04%2026-03-24

1 of 1

Forecast return on equity

Is GENB forecast to generate an efficient return?

Company
-56.55%
Industry
15.5%
Market
167.59%
GENB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GENB forecast to generate an efficient return on assets?

Company
-45.92%
Industry
23.42%
GENB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GENB earnings per share forecast

What is GENB's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$2.32
Avg 2 year Forecast
-$2.34
Avg 3 year Forecast
-$1.82

GENB revenue forecast

What is GENB's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$30.3M
Avg 2 year Forecast
$33.9M
Avg 3 year Forecast
$125.4M

GENB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GENB$16.39$26.40+61.07%Strong Buy
KLRA$16.23$38.00+134.13%Strong Buy
COAG$44.41$51.40+15.74%Strong Buy
ZYME$29.19$40.25+37.89%Strong Buy
AUPH$16.08$16.00-0.50%Hold
View Top Biotech Stocks

Generate Biomedicines Stock Forecast FAQ

Is Generate Biomedicines Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: GENB) stock is to Strong Buy GENB stock.

Out of 6 analysts, 5 (83.33%) are recommending GENB as a Strong Buy, 1 (16.67%) are recommending GENB as a Buy, 0 (0%) are recommending GENB as a Hold, 0 (0%) are recommending GENB as a Sell, and 0 (0%) are recommending GENB as a Strong Sell.

If you're new to stock investing, here's how to buy Generate Biomedicines stock.

What is GENB's earnings growth forecast for 2026-2028?

(NASDAQ: GENB) Generate Biomedicines's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.04%.

Generate Biomedicines's earnings in 2026 is N/A.On average, 8 Wall Street analysts forecast GENB's earnings for 2026 to be -$298,278,226, with the lowest GENB earnings forecast at -$314,463,468, and the highest GENB earnings forecast at -$288,407,924. On average, 8 Wall Street analysts forecast GENB's earnings for 2027 to be -$300,460,217, with the lowest GENB earnings forecast at -$342,136,253, and the highest GENB earnings forecast at -$206,198,188.

In 2028, GENB is forecast to generate -$233,036,683 in earnings, with the lowest earnings forecast at -$359,746,208 and the highest earnings forecast at -$122,640,753.

What is GENB's revenue growth forecast for 2026-2028?

(NASDAQ: GENB) Generate Biomedicines's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.43%.

Generate Biomedicines's revenue in 2026 is N/A.On average, 8 Wall Street analysts forecast GENB's revenue for 2026 to be $3,886,255,057, with the lowest GENB revenue forecast at $2,955,956,601, and the highest GENB revenue forecast at $5,188,647,225. On average, 8 Wall Street analysts forecast GENB's revenue for 2027 to be $4,352,816,162, with the lowest GENB revenue forecast at $2,997,671,143, and the highest GENB revenue forecast at $5,390,802,312.

In 2028, GENB is forecast to generate $16,099,246,047 in revenue, with the lowest revenue forecast at $4,644,047,839 and the highest revenue forecast at $39,083,316,762.

What is GENB's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: GENB) forecast ROA is -45.92%, which is lower than the forecast US Biotechnology industry average of 23.42%.

What is GENB's Price Target?

According to 5 Wall Street analysts that have issued a 1 year GENB price target, the average GENB price target is $26.40, with the highest GENB stock price forecast at $30.00 and the lowest GENB stock price forecast at $22.00.

On average, Wall Street analysts predict that Generate Biomedicines's share price could reach $26.40 by Aug 28, 2027. The average Generate Biomedicines stock price prediction forecasts a potential upside of 61.07% from the current GENB share price of $16.39.

What is GENB's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: GENB) Generate Biomedicines's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that GENB's EPS will be -$2.32 for 2026, with the lowest EPS forecast at -$2.45, and the highest EPS forecast at -$2.25. On average, analysts forecast that GENB's EPS will be -$2.34 for 2027, with the lowest EPS forecast at -$2.67, and the highest EPS forecast at -$1.61. In 2028, GENB's EPS is forecast to hit -$1.82 (min: -$2.80, max: -$0.96).

What is GENB's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: GENB) forecast ROE is -56.55%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.